| Name | Ethosuximide |
| Description | Ethosuximide (Zarontin) is an anticonvulsant, blocks the low voltage-activated T-type calcium channel used in the treatment of absence seizures unaccompanied by other types of seizures. |
| Cell Research | Mouse Neuro2A (N2A) neuroblastoma cells are cultured on 6-well plates and treated with retinoic acid to induce neuronal differentiation. After 24 h, N2A cells are treated with vehicle control (PBS) or increasing concentrations of ethosuximide for 5 h. Total RNA is then isolated, DNase-treated and reverse transcribed to cDNA. qRT-PCR is run above normalising to the reference genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin (ACTB). (Only for Reference) |
| In vitro | Ethosuximide(ETH) enhances hippocampal derived NSC proliferation and neurospheres formation in vitro. Low concentration of ETH induces proliferation of NSC, while higher concentrations of ETH are cytotoxic. Also, ETH activates the PI3K/Akt signal transduction pathway in adult hippocampal NSC in vitro. Blockade of the PI3K/Akt pathway inhibits ETH induced hippocampal NSC neuronal differentiation[3]. |
| In vivo | Anti-epileptic drug ethosuximide rescues the short lifespan and chemosensory defects exhibited by C. elegans null mutants of dnj-14, the worm orthologue of the DNAJC5 gene mutated in autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. It also ameliorates the locomotion impairment and short lifespan of worms expressing a human Tau mutant that causes frontotemporal dementia[1]. Ethosuximide extends lifespan by inhibiting the function of specific chemosensory neurons[2]. It increases neurogenesis, reduces neurodegeneration, and reverses cognitive impairments in rat model of AD like phenotypes[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (14.17 mM), Sonication is recommended.
H2O : 198.3 mM, Sonication is recommended.
DMSO : 50 mg/mL (354.18 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | Ethosuximide | CalciumChannel | Calcium Channel | Ca2+ channels | Ca channels |
| Inhibitors Related | Quadrol | Tricaine methanesulfonate | Nisoldipine | 2,4,6-Tri-tert-butylphenol | L-Ascorbic acid | L-Phenylalanine | Ethyl cinnamate | L-Ascorbic acid sodium salt | 1-Octanol | 2-Nitrobenzoic acid | Magnesium Chloride Hexahydrate | Magnesium sulfate |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Tobacco Monomer Library | Neuroprotective Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |
United States
